^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SC0191

    i
    Other names: SC0191
    Company:
    Shijiazhuang Sagacity, WuXi AppTec, Wuxi Biocity
    Drug class:
    WEE1 inhibitor
    Related drugs:
    4years
    [VIRTUAL] Preclinical evaluation of SC0191, a small molecule inhibitor of Wee1 kinase. (ASCO 2020)
    Moreover, SC0191 oral administration showed significant antitumor efficacy which was better than AZD1775, in the NCI-H446 and BxPC-3 CDX mouse models, respectively. A novel Wee1 inhibitor, SC0191, has demonstrated excellent antitumor efficacy in TP53 mutant solid cancer preclinical studies, and represents a promising clinical candidate for treating solid tumors, such as SCLC and PC. Research Funding: Sagacity
    Preclinical
    |
    TP53 (Tumor protein P53) • CDK1 (Cyclin-dependent kinase 1)
    |
    TP53 mutation
    |
    adavosertib (AZD1775) • SC0191